

## Trends in the management and the effects on oncologic outcomes in patients with upper tract urothelial carcinoma

Guest Editor



**Ho Seok Chung**

MD, PhD, Associate  
Professor, Department of  
Urology, Chonnam  
National University  
Hwasun Hospital,  
Republic of Korea  
[hschung615@gmail.com](mailto:hschung615@gmail.com)

Submission deadline  
**30 December 2021**

More Details



Dear colleagues,

Urothelial carcinoma (UC) is the 5th most common malignancy. Upper tract urothelial carcinoma (UTUC), located in the pyelocaliceal cavity and ureter, is an uncommon disease with potentially aggressive behavior and accounts for only 5–10% of UCs. UTUC is a rare disease and has potentially aggressive tumor characteristics. RNU with a bladder cuff excision has been the standard treatment regardless of tumor location in patients with UTUC and clinically non-metastatic disease. In selective patients, nephron-sparing surgery could be the treatment option for UTUC, including ureteroscopy, percutaneous approaches, and segmental ureterectomy. In locally advanced UTUC, still, there is a lack of evidence supporting the clinical benefit of neoadjuvant/adjuvant chemotherapy. The introduction of immune checkpoint inhibitors led to a paradigm shift in the treatment of locally advanced/unresectable or metastatic UTUC for cisplatin-ineligible patients or after platinum-based chemotherapy.

This Special Issue aims to share your research and clinical experiences for the physicians in the diagnosis and management of upper tract urothelial cancer.

Ho Seok Chung

*Guest Editor*

**Keywords:** chemotherapy, drug therapy, neoplasms, surgical procedure, urogenital system, urothelial carcinoma

**More information:** <https://www.jomh.org/special-issues/1371377748600078336>